Thursday, December 12, 2013
National University of Singapore and St. Jude Children's
Research Hospital team has engineered a T cell
therapeutic that can engage in antibody-dependent cell cytotoxicity and enhance
the effects of therapeutic antibodies regardless of the target tumor antigen.1
The researchers showed proof of concept for boosting the efficacy of multiple
marketed cancer antibodies.
T. SciBX 6(47);
doi:10.1038/scibx.2013.1337 Published online Dec. 12, 2013
1. Kudo, K. et al.
Cancer Res.; published online Nov. 6, 2013;
doi:10.1158/0008-5472.CAN-13-1365 Contact: Dario Campana, National
University of Singapore, Singapore e-mail: firstname.lastname@example.org
2. Clémenceau, B. et
al. Blood 107, 4669-4677 (2006)
3. Imai, C. et al.
Leukemia 18, 676-684 (2004)
AND INSTITUTIONS MENTIONED
Abramson Family Cancer Research Institute at the University
Atlas Venture, Cambridge, Mass.
Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass.
Geisel School of Medicine at Dartmouth, Hanover, N.H.
Genentech Inc., South San Francisco, Calif.
MaxCyte Inc., Gaithersburg, Md.
National University of Singapore, Singapore
of Medicine at the University of Pennsylvania, Philadelphia, Pa.
Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
St. Jude Children's Research Hospital, Memphis, Tenn.